Biologic Significance of Reduced Levels of Glucose Degradation Products

Krediet R.T. , Zweers M.M. , Ho-dac-Pannekeet M.M. The effect of various dialysis solutions on peritoneal membrane viability. Perit Dial Int 1999; 19(Suppl 2): S257–66.

Wieslander A. , Nordin M.K. , Kjellstrand P.T. , Boberg U. Toxicity of peritoneal dialysis fluids on cultured fibroblasts L-929. Kidney Int 1991; 40: 77–9.

Kjellstrand P. , Martinson E. , Wieslander A. , Holmquist B. Development of toxic degradation products during heat-sterilization of glucose-containing fluids for peritoneal dialysis: influence of time and temperature. Perit Dial Int 1995; 15: 26–32.

Nilsson–Thorell C. , Muscalu N. , Andrén A.H.G. , Kjellstrand P. , Wieslander A. The heat-sterilization of fluids for peritoneal dialysis gives rise to several aldehydes. Perit Dial Int 1993; 13: 208–13.

Lindén T. , Forsbäck G. , Deppisch R. , Henle T. , Wieslander A. 3-Deoxyglucosone, a promoter of advanced glycation end-products in fluids for peritoneal dialysis. Perit Dial Int 1998; 18: 290–3.

Barile F.A. Introduction to In Vitro Cytotoxicology: Mechanisms and Methods. Boca Raton: CRC Press; 1994: 27–35.

Wieslander A. , Nordin M. , Martinson E. , Kjellstrand P. , Boberg U. Heat-sterilized PD-fluids impair growth and inflammatory responses of cultured cell lines and human leukocytes. Clin Nephrol 1993; 39(6): 343–8.

Wieslander A. , Andrén A.H.G. , Nilsson–Thorell C. , Muscalu N. , Kjellstrand P. , Rippe B. Are aldehydes in heat-sterilized peritoneal dialysis fluids toxic in vitro? Perit Dial Int 1995; 15: 348–52.

Dawnay A. , Wieslander A P. , Millar D.J. Role of glucose degradation products in the generation of characteristic AGE fluorescence in peritoneal dialysis fluid. In: O'Brien J. , Nursten H.E. , Crabbe J.C. , Ames J.A. , eds. The Maillard Reaction in Foods and Medicine. Proceedings of the 6th International Symposium on the Maillard reaction; 27–30 July 1997; London, U.K. London: The Royal Society of Chemistry; 1997: 332–7.

Nakayama M. , Kawaguchi Y. , Yamada K. , Hasegawa T. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997; 51: 182–6.

Jonasson P. , Bagge U. , Wieslander A. , Braide M. Heat-sterilized PD-fluid blocks leukocyte adhesion and increases flow velocity in rat peritoneal venules. Perit Dial Int 1996; 16(Suppl 1): S137–40.

Musi B. , Rippe A. , Carlsson O. , Wieslander A. , Rippe B. Effects of acidity, glucose degradation products, and dialysis fluid buffer choice on peritoneal solute and fluid transport in rats. Perit Dial Int 1998; 18: 303–10.

Musi B. , Braide M. , Wieslander A. , Rippe A. , Albrektsson A. , Henle T. Very high daily intraperitoneal doses of carbonyl compounds affect the morphology, but not the exchange characteristics, of rat peritoneum. Blood Purif 2001; 19: 286–92.

Rippe B. , Simonsen O. , Wieslander A.P. , Landgren C. Clinical and physiological effects of a new, less toxic and less acidic fluid for peritoneal dialysis. Perit Dial Int 1997; 17: 27–34.

Rippe B. , Simonsen O. , Heimbürger O. , Christensson A. , Haraldsson B. , Stelin G. Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001; 59: 348–57.

Pannekeet M.M. , Zemel D. , Koomen G.C.M. , Struijk D.G. , Krediet R.T. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 1995; 15: 217–25.

Heimbürger O. , Waniewski J. , Werynski A. , Tranæus A. , Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38: 495–506.

Visser C.E. , Brouwer–Steenbergen J.J.E. , Betjes M.G.H. , Koomen G.C.M. , Beelen R.H.J. , Krediet R.T. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patient. Nephrol Dial Transplant 1995; 10: 64–9.

Rippe B. , Krediet R.T. Peritoneal physiology. Transport of solutes. In: Gokal R.C. , Nolph K.D. , eds. The Textbook of Peritoneal Dialysis. Dordrecht: Kluwer Academic Publishers; 1994: 68–132.

Yung S. , Coles G.A. , Williams J.D. , Davies M. The source and possible significance of hyaluronan in the peritoneal cavity. Kidney Int 1994; 46: 527–33.

Laurent T.C. , Laurent U.B.G. , Fraser J.R.E. The structure and function of hyaluronan: an overview. Immunol Cell Biol 1996; 74: A1–7.

Yung S. , Coles G.A. , Davies M. IL-1β, a major stimulator of hyaluronan synthesis in vitro of human peritoneal mesothelial cells: relevance to peritonitis in CAPD. Kidney Int 1996; 50: 1337–43.

Risteli L. The carboxyterminal propeptide of pro-collagen type I (PICP) in serum and biological fluids. Scand J Clin Lab Invest Suppl 1990; 202: 143–6.

Graff J. , Joffe P. , Fugleberg S. Collagen markers in peritoneal dialysis patients. Adv Perit Dial 1995; 11: 24–7.

Inagi R. , Miyata T. , Yamamoto T. , Susuki D. , Urakami K. , Saito A. Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: role in the functional and morphological alterations of peritoneal membranes in peritoneal dialysis. FEBS Lett 1999; 463: 260–4.

Jones S. , Holmes C.J. , Krediet R.T. , Mackenzie R. , Faict D. , Tranæus A. Bicarbonate/lactate–based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59: 1529–38.